elvanse 30 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 30 mg
elvanse 20 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 20 mg
elvanse 40 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 40 mg
elvanse 50 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 50 mg
elvanse 60 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 60 mg
elvanse 70 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 70 mg
aduvanz 50 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 50 mg
aduvanz 30 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 30 mg
aduvanz 70 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 70 mg
takhzyro
takeda pharmaceuticals international ag ireland branch - lanadelumab - angioødemer, arvelig - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.